{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:54:22Z","timestamp":1793498062113,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"30","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 DK100653"],"award-info":[{"award-number":["RO1 DK100653"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK123694"],"award-info":[{"award-number":["R01 DK123694"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options. The lack of mouse models that recapitulate the genetics of ACC has hampered progress in the field. We analyzed The Cancer Genome Atlas (TCGA) dataset for ACC and found that patients harboring alterations in both p53\/Rb and Wnt\/\u03b2-catenin signaling pathways show a worse prognosis compared with patients that harbored alterations in only one. To model this, we utilized the\n                    <jats:italic>Cyp11b2(AS)<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>Cre<\/jats:italic>\n                    <\/jats:sup>\n                    mouse line to generate mice with adrenocortical-specific Wnt\/\u03b2-catenin activation,\n                    <jats:italic>Trp53<\/jats:italic>\n                    deletion, or the combination of both. Mice with targeted Wnt\/\u03b2-catenin activation or\n                    <jats:italic>Trp53<\/jats:italic>\n                    deletion showed no changes associated with tumor formation. In contrast, alterations in both pathways led to ACC with pulmonary metastases. Similar to ACCs in humans, these tumors produced increased levels of corticosterone and aldosterone and showed a high proliferation index. Gene expression analysis revealed that mouse tumors exhibited downregulation of\n                    <jats:italic>Star<\/jats:italic>\n                    and\n                    <jats:italic>Cyp11b1<\/jats:italic>\n                    and upregulation of\n                    <jats:italic>Ezh2<\/jats:italic>\n                    , similar to ACC patients with a poor prognosis. Altogether, these data show that altering both Wnt\/\u03b2-catenin and p53\/Rb signaling is sufficient to drive ACC in mouse. This autochthonous model of ACC represents a new tool to investigate the biology of ACC and to identify new treatment strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41388-020-1358-5","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T14:02:54Z","timestamp":1592575374000},"page":"5282-5291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice"],"prefix":"10.1038","volume":"39","author":[{"given":"Kleiton Silva","family":"Borges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-5692","authenticated-orcid":false,"given":"Emanuele","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-493X","authenticated-orcid":false,"given":"Sining","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulanjalee","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Ruiz-Babot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Silva","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto Mark","family":"Taketo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"Carlone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-4857","authenticated-orcid":false,"given":"David T.","family":"Breault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282\u2013326.","journal-title":"Endocr Rev"},{"key":"1358_CR2","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","volume":"98","author":"M Fassnacht","year":"2013","unstructured":"Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1\u201346.","journal-title":"Eur J Endocrinol"},{"key":"1358_CR4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","volume":"99","author":"T Else","year":"2014","unstructured":"Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/js.2018-00197","volume":"2","author":"DR Mohan","year":"2018","unstructured":"Mohan DR, Lerario AM, Hammer GD. Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc. 2018;2:1259\u201374.","journal-title":"J Endocr Soc"},{"key":"1358_CR6","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","volume":"103","author":"J Lippert","year":"2018","unstructured":"Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103:4511\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fendo.2016.00093","volume":"7","author":"F Leccia","year":"2016","unstructured":"Leccia F, Batisse-Lignier M, Sahut-Barnola I, Val P, Lefran\u00e7ois-Martinez AM, Martinez A. Mouse models recapitulating human adrenocortical tumors: what is lacking? Front Endocrinol. 2016;7:93.","journal-title":"Front Endocrinol"},{"key":"1358_CR8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2015.11.031","volume":"421","author":"KJ Basham","year":"2016","unstructured":"Basham KJ, Hung HA, Lerario AM, Hammer GD. Mouse models of adrenocortical tumors. Mol Cell Endocrinol. 2016;421:82\u201397.","journal-title":"Mol Cell Endocrinol"},{"key":"1358_CR9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assi\u00e9","year":"2014","unstructured":"Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607\u201312.","journal-title":"Nat Genet"},{"key":"1358_CR10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"1358_CR11","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","volume":"70","author":"B Ragazzon","year":"2010","unstructured":"Ragazzon B, Lib\u00e9 R, Gaujoux S, Assi\u00e9 G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276\u201381.","journal-title":"Cancer Res"},{"key":"1358_CR12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/hmg\/ddq029","volume":"19","author":"A Berthon","year":"2010","unstructured":"Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, et al. Constitutive \u03b2-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet. 2010;19:1561\u201376.","journal-title":"Hum Mol Genet"},{"key":"1358_CR13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ajpath.2012.05.026","volume":"181","author":"JH Heaton","year":"2012","unstructured":"Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and \u03b2-catenin. Am J Pathol. 2012;181:1017\u201333.","journal-title":"Am J Pathol"},{"key":"1358_CR14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1101\/gad.317412.118","volume":"33","author":"KJ Basham","year":"2019","unstructured":"Basham KJ, Rodriguez S, Turcu AF, Lerario AM, Logan CY, Rysztak MR, et al. A ZNRF3-dependent Wnt\/\u03b2-catenin signaling gradient is required for adrenal homeostasis. Genes Dev. 2019;33:209\u201320.","journal-title":"Genes Dev"},{"key":"1358_CR15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044171","volume":"7","author":"C Drelon","year":"2012","unstructured":"Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS ONE. 2012;7:e44171.","journal-title":"PLoS ONE"},{"key":"1358_CR16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"1358_CR17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413\u201331.","journal-title":"Cell"},{"key":"1358_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.010","volume":"351","author":"JD Wasserman","year":"2012","unstructured":"Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol. 2012;351:101\u201310.","journal-title":"Mol Cell Endocrinol"},{"key":"1358_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2011.12.008","volume":"351","author":"T Else","year":"2012","unstructured":"Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol. 2012;351:66\u201370.","journal-title":"Mol Cell Endocrinol"},{"key":"1358_CR20","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni Syndrome Cohort. Cancer. 2016;122:3673\u201381.","journal-title":"Cancer"},{"key":"1358_CR21","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1073\/pnas.161479898","volume":"98","author":"RC Ribeiro","year":"2001","unstructured":"Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98:9330\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1358_CR22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/356215a0","volume":"356","author":"LA Donehower","year":"1992","unstructured":"Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215\u201321.","journal-title":"Nature"},{"key":"1358_CR23","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1158\/0008-5472.CAN-18-0016","volume":"78","author":"JH Park","year":"2018","unstructured":"Park JH, Li J, Starost MF, Liu C, Zhuang J, Chen J, et al. Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis. Cancer Res. 2018;78:5375\u201383.","journal-title":"Cancer Res"},{"key":"1358_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1358_CR25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.devcel.2013.07.016","volume":"26","author":"BD Freedman","year":"2013","unstructured":"Freedman BD, Kempna PB, Carlone DL, Shah M, Guagliardo NA, Barrett PQ, et al. Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. Dev Cell. 2013;26:666\u201373.","journal-title":"Dev Cell"},{"key":"1358_CR26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1101\/gad.14.8.994","volume":"14","author":"S Marino","year":"2000","unstructured":"Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994\u20131004.","journal-title":"Genes Dev"},{"key":"1358_CR27","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1093\/emboj\/18.21.5931","volume":"18","author":"N Harada","year":"1999","unstructured":"Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999;18:5931\u201342.","journal-title":"EMBO J"},{"key":"1358_CR28","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1242\/dev.021493","volume":"135","author":"AC Kim","year":"2008","unstructured":"Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development. 2008;135:2593\u2013602.","journal-title":"Development"},{"key":"1358_CR29","first-page":"5187","volume":"55","author":"T Waldman","year":"1995","unstructured":"Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55:5187\u201390.","journal-title":"Cancer Res"},{"key":"1358_CR30","doi-asserted-by":"crossref","first-page":"107524","DOI":"10.1016\/j.celrep.2020.107524","volume":"31","author":"E Pignatti","year":"2020","unstructured":"Pignatti E, Leng S, Yuchi Y, Guagliardo NA, Borges KS, Shah MS, et al. Beta-catenin causes adrenal hyperplasia by blocking zonal transdifferentiation. Cell Rep. 2020;31:107524.","journal-title":"Cell Rep."},{"key":"1358_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","volume":"8","author":"LM Weiss","year":"1984","unstructured":"Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163\u20139.","journal-title":"Am J Surg Pathol"},{"key":"1358_CR32","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagner\u00e9 AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622\u20137.","journal-title":"Cancer Res"},{"key":"1358_CR33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0090-4295(00)00852-9","volume":"57","author":"M Terzolo","year":"2001","unstructured":"Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Al\u00ec A, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology. 2001;57:176\u201382.","journal-title":"Urology"},{"key":"1358_CR34","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","volume":"95","author":"S Sbiera","year":"2010","unstructured":"Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR35","volume":"11","author":"S Leng","year":"2020","unstructured":"Leng S, Pignatti E, Khetani RS, Shah MS, Xu S, Miao J, et al. \u03b2-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. Nat Commun. 2020;11:1680.","journal-title":"Nat Commun"},{"key":"1358_CR36","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","volume":"91","author":"G Abiven","year":"2006","unstructured":"Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/ERC-18-0385","volume":"26","author":"IC Mouat","year":"2019","unstructured":"Mouat IC, Omata K, McDaniel AS, Hattangady NG, Talapatra D, Cani AK, et al. Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. Endocr Relat Cancer. 2019;26:217\u201325.","journal-title":"Endocr Relat Cancer"},{"key":"1358_CR38","first-page":"2789","volume":"25","author":"C Drelon","year":"2016","unstructured":"Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Tabbal H, et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet. 2016;25:2789\u2013800.","journal-title":"Hum Mol Genet"},{"key":"1358_CR39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","volume":"65","author":"P Haluska","year":"2010","unstructured":"Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharm. 2010;65:765\u201373.","journal-title":"Cancer Chemother Pharm"},{"key":"1358_CR40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","volume":"21","author":"RL Jones","year":"2015","unstructured":"Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015;21:693\u2013700.","journal-title":"Clin Cancer Res"},{"key":"1358_CR41","first-page":"618","volume":"1","author":"A Zsippai","year":"2011","unstructured":"Zsippai A, Szab\u00f3 DR, Szab\u00f3 PM, T\u00f6mb\u00f6l Z, Bendes MR, Nagy Z, et al. mRNA and microRNA expression patterns in adrenocortical cancer. Am J Cancer Res. 2011;1:618\u201328.","journal-title":"Am J Cancer Res"},{"key":"1358_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12751","volume":"7","author":"C Drelon","year":"2016","unstructured":"Drelon C, Berthon A, Sahut-Barnola I, Mathieu M, Dumontet T, Rodriguez S, et al. PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development. Nat Commun. 2016;7:12751.","journal-title":"Nat Commun"},{"key":"1358_CR43","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-17-0976","volume":"179","author":"SS Pereira","year":"2018","unstructured":"Pereira SS, Monteiro MP, Lacroix A, Pignatelli D. MECHANISMS OF ENDOCRINOLOGY: cell cycle regulation in adrenocortical carcinoma. Eur J Endocrinol. 2018;179:R95\u2013110.","journal-title":"Eur J Endocrinol"},{"key":"1358_CR44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coemr.2019.07.006","volume":"8","author":"D Mohan","year":"2019","unstructured":"Mohan D, Lerario AM, Finco I, Hammer G. New strategies for applying targeted therapies to adrenocortical carcinoma. Curr Opin Endocr Metab Res. 2019;8:72\u20139.","journal-title":"Curr Opin Endocr Metab Res"},{"key":"1358_CR45","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2011-0363","volume":"96","author":"LF Leal","year":"2011","unstructured":"Leal LF, Mermejo LM, Ramalho LZ, Martinelli CE Jr, Yunes JA, Seidinger AL, et al. Wnt\/beta-catenin pathway deregulation in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2011;96:3106\u2013114.","journal-title":"J Clin Endocrinol Metab"},{"key":"1358_CR46","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1200\/JCO.2017.74.2460","volume":"10","author":"EM Pinto","year":"2017","unstructured":"Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a St Jude Adrenocortical Tumor Registry and Children\u2019s Oncology Group Study. J Clin Oncol. 2017;10:3956\u201363.","journal-title":"J Clin Oncol"},{"key":"1358_CR47","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/ERC-17-0361","volume":"25","author":"F Bonnet-Serrano","year":"2018","unstructured":"Bonnet-Serrano F, Bertherat J. Genetics of tumors of the adrenal cortex. Endocr Relat Cancer. 2018;25:R131\u201352.","journal-title":"Endocr Relat Cancer"},{"key":"1358_CR48","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1038\/onc.2017.54","volume":"36","author":"M Batisse-Lignier","year":"2017","unstructured":"Batisse-Lignier M, Sahut-Barnola I, Tissier F, Dumontet T, Mathieu M, Drelon C, et al. P53\/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model. Oncogene. 2017;36:4445\u201356.","journal-title":"Oncogene"},{"key":"1358_CR49","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1038\/sj.onc.1209046","volume":"24","author":"D Ahuja","year":"2005","unstructured":"Ahuja D, S\u00e1enz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 2005;24:7729\u201345.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1358-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:21:24Z","timestamp":1684603284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1358-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":49,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2020,7,23]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1358-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738178514.793594868","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"29 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal procedures were approved by the Boston Children\u2019s Hospital Institutional Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}